PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24996009-5 2014 The ACE inhibitor enalapril (1 0 or 0 2 mg/kg/day) was administered orally to EAE mice and the serum levels of bradykinin and cytokines in EAE mice were analysed. Enalapril 18-27 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 4-7 25037058-0 2014 Adiponectin expression and the cardioprotective role of the vitamin D receptor activator paricalcitol and the angiotensin converting enzyme inhibitor enalapril in ApoE-deficient mice. Enalapril 150-159 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 110-139 24216112-0 2013 Angiotensin-converting enzyme inhibitor (enalapril maleate) accelerates recovery of mouse skin from UVB-induced wrinkles. Enalapril 41-58 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 0-29 24239644-1 2014 AIMS: Enalapril, an angiotensin-converting enzyme (ACE) inhibitor, has pleiotropic effects such as anti-inflammatory effects. Enalapril 6-15 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 20-49 24239644-1 2014 AIMS: Enalapril, an angiotensin-converting enzyme (ACE) inhibitor, has pleiotropic effects such as anti-inflammatory effects. Enalapril 6-15 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 51-54 24216112-3 2013 In this study, we examined the effect of enalapril maleate, an ACE inhibitor, on recovery of wrinkled skin of hairless mice exposed to long-term UVB irradiation. Enalapril 41-58 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 63-66 24216112-6 2013 Our results indicate that ACE and angiotensin II activity are involved in skin photoaging, and suggest that ACE inhibitor such as enalapril maleate may have potential for improvement of photoaged skin. Enalapril 130-147 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 26-29 24216112-6 2013 Our results indicate that ACE and angiotensin II activity are involved in skin photoaging, and suggest that ACE inhibitor such as enalapril maleate may have potential for improvement of photoaged skin. Enalapril 130-147 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 108-111 23673415-5 2013 We have tested the hypothesis that ACE inhibition decreases fibrosis in dystrophic skeletal muscle by treatment of mdx mice with the ACE inhibitor enalapril. Enalapril 147-156 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 35-38 23846498-4 2013 Coinfusion of an ACE inhibitor, enalapril, ablated angiotensin I-augmented atherosclerosis but had no effect on angiotensin II-induced lesion development. Enalapril 32-41 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 17-20 23894285-8 2013 CONCLUSION: Our findings indicate that ACE inhibition with enalapril attenuated several of the deleterious effects of the HF diet. Enalapril 59-68 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 39-42 23673415-5 2013 We have tested the hypothesis that ACE inhibition decreases fibrosis in dystrophic skeletal muscle by treatment of mdx mice with the ACE inhibitor enalapril. Enalapril 147-156 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 133-136 20627092-6 2010 Perindopril (1mg/kg/day), imidapril (3mg/kg/day), or enalapril (10mg/kg/day) all inhibited the plasma ACE activities by more than 90%. Enalapril 53-62 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 102-105 22752270-2 2012 Herein, we assessed the effects of prophylactic and therapeutic treatment with the angiotensin-converting enzyme (ACE) inhibitor, enalapril, on APAP-caused hepatotoxicity. Enalapril 130-139 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 83-112 22752270-2 2012 Herein, we assessed the effects of prophylactic and therapeutic treatment with the angiotensin-converting enzyme (ACE) inhibitor, enalapril, on APAP-caused hepatotoxicity. Enalapril 130-139 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 114-117 21622682-4 2011 Either losartan (an Ang II receptor-1 antagonist, AT(1)) or enalapril (an ACE inhibitor), but not chymostatin (a chymase inhibitor), inhibited Ang I-induced responses. Enalapril 60-69 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 74-77 19854435-0 2010 The ACE inhibitors enalapril and captopril modulate cytokine responses in Balb/c and C57Bl/6 normal mice and increase CD4(+)CD103(+)CD25(negative) splenic T cell numbers. Enalapril 19-28 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 4-7 19854435-6 2010 To verify that, in this work, we investigated the effects of treatment with the ACE inhibitors enalapril and captopril on cytokine synthesis in C57Bl/6 and Balb/c mice. Enalapril 95-104 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 80-83 19939336-9 2009 Treatment with enalapril (an ACE inhibitor) almost completely prevented the development of accelerated aortic atherosclerosis in uremic mice. Enalapril 15-24 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 29-32 18847324-7 2009 Finally, treatment of THM mice with an ACE inhibitor, enalapril, improved osteoporosis and hypertension, whereas treatment with losartan, an angiotensin receptor blockers specific for AT1, resulted in exacerbation of the low bone mass phenotype. Enalapril 54-63 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 39-42 19255283-6 2009 In SCID mice, the ACE inhibitor, enalapril (C(20)H(28)N(2)O(5) x C(4)H(4)O(4)) at 30 mg/kg, prevented hypertension, with no attenuation of the antitumor efficacy of ABT-869. Enalapril 33-42 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 18-21 19258495-8 2009 Interestingly, ACE inhibition (enalapril) and ANG II AT(1) receptor blocker (losartan) reduced intima thickening in 3-copy mice to 1-copy mouse values (P < 0.05) while ANG II treatment significantly increased intima thickening in 1-copy mice to 3-copy mouse levels (P < 0.05). Enalapril 31-40 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 15-18 35113975-9 2022 As expected, enalapril administration lowered BP, plasma angiotensin II and organ ACE activity in control mice. Enalapril 13-22 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 82-85 15585195-3 2005 This study was undertaken to determine whether enalapril, an ACE inhibitor, prevents atherosclerosis and vascular inflammation induced by Ang II in apolipoprotein E-deficient (apoE-KO) mice. Enalapril 47-56 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 61-64 14597675-4 2003 We demonstrate that a decrease in the amount of circulating ANG II by the angiotensin-converting enzyme (ACE) inhibitor enalapril or the AT1 receptor antagonist losartan induced a stimulation of in vivo angiogenesis implying an inhibitory function of ANG II through the AT1 receptor. Enalapril 120-129 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 74-103 14597675-4 2003 We demonstrate that a decrease in the amount of circulating ANG II by the angiotensin-converting enzyme (ACE) inhibitor enalapril or the AT1 receptor antagonist losartan induced a stimulation of in vivo angiogenesis implying an inhibitory function of ANG II through the AT1 receptor. Enalapril 120-129 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 105-108 10712274-8 2000 These findings support our previous reports on the enalapril- and captopril-induced enhancement of endogenous antioxidant defenses and include new data on glutathione-dependent defenses, thus furthering current knowledge on the association of ACE inhibition and antioxidants. Enalapril 51-60 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 243-246 2138337-1 1990 The angiotensin converting enzyme (ACE) inhibitors captopril and enalapril and the nootropic piracetam reduced the amnesiogenic effects of cerebral electroshock treatment in mice. Enalapril 65-74 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 4-33 17082641-5 2006 Pretreatment of mice with the angiotensin-converting enzyme (ACE) inhibitor enalapril, but not the anti-hypertensive hydralazine, decreased pulmonary neutrophil recruitment after exposure to LPS. Enalapril 76-85 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 61-64 16824557-3 2006 In contrast, an ACE inhibitor, enalapril, did not reduce the brain ischemic area, and neurological deficit even at a hypotensive dose. Enalapril 31-40 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 16-19 12546633-4 2003 Mice underwent sham procedure or left coronary artery ligation, and received placebo, the AT(1) receptor antagonist, losartan or the ACE inhibitor, enalapril. Enalapril 148-157 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 133-136 12003776-1 2002 The present study was undertaken to investigate the effects of treatment with the angiotensin-converting enzyme (ACE) inhibitor enalapril in a mouse model of pulmonary hypertension induced by bleomycin. Enalapril 128-137 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 82-111 12003776-1 2002 The present study was undertaken to investigate the effects of treatment with the angiotensin-converting enzyme (ACE) inhibitor enalapril in a mouse model of pulmonary hypertension induced by bleomycin. Enalapril 128-137 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 113-116 9606736-2 1998 In the present study, we demonstrated the preventive effects of enalapril, an angiotensin converting enzyme (ACE) inhibitor, on the progression of renal dysfunction and tubulo-interstitial fibrosis in the NS mice. Enalapril 64-73 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 78-107 9606736-2 1998 In the present study, we demonstrated the preventive effects of enalapril, an angiotensin converting enzyme (ACE) inhibitor, on the progression of renal dysfunction and tubulo-interstitial fibrosis in the NS mice. Enalapril 64-73 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 109-112 8046949-11 1994 In conclusion, the effects of ACE inhibitors such as captopril and enalapril on Con A-induced T-lymphocyte proliferation were confirmed after a pilot study recently reported. Enalapril 67-76 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 30-33 8390488-4 1993 Captopril, an angiotensin-converting enzyme (ACE) inhibitor and potent free radical scavenger with a sulfhydryl group, was effective for the treatment of viral myocarditis, while enalapril, an ACE inhibitor without a sulfhydryl group, was not effective against acute myocarditis. Enalapril 179-188 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 45-48 2159503-1 1990 The short-term and long-term effects (for up to 98 days) of the angiotensin converting enzyme inhibitor enalapril were investigated in male and female BALB/c mice. Enalapril 104-113 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 64-93 2138337-1 1990 The angiotensin converting enzyme (ACE) inhibitors captopril and enalapril and the nootropic piracetam reduced the amnesiogenic effects of cerebral electroshock treatment in mice. Enalapril 65-74 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 35-38 35319673-5 2022 Male ELA-2 KO and C57BL/6 mice were treated with the ACE inhibitor enalapril or saline for 10 days. Enalapril 67-76 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 53-56 34793332-6 2022 Treatment of AS mice with hyaluronidase or the ACE inhibitor enalapril reduced the excess glomerular endothelial glycocalyx and blocked immune cell homing, and GFB albumin leakage. Enalapril 61-70 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 47-50 33049402-0 2021 Enalapril improves obesity associated liver injury ameliorating systemic metabolic markers by modulating Angiotensin Converting Enzymes ACE/ACE2 expression in high-fat feed mice. Enalapril 0-9 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 136-139 6195268-6 1983 Treatment of infected mice with MK421, another specific ACE inhibitor, decreased granuloma ACE activity and AII content and size. Enalapril 32-37 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 56-59 6195268-6 1983 Treatment of infected mice with MK421, another specific ACE inhibitor, decreased granuloma ACE activity and AII content and size. Enalapril 32-37 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 91-94 33476653-8 2021 The ACE inhibitors enalapril and captopril enhanced reserpine-induced mechanical allodynia, and this increase was prevented by kinin B1 and B2 receptor antagonists. Enalapril 19-28 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 4-7 33049402-10 2021 Hepatic echogenicity and steatosis measurement were lower in the obese groups treated with Enalapril also modulating ACE2/ACE expressions. Enalapril 91-100 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 117-120 33049402-11 2021 CONCLUSIONS: Enalapril use improved metabolism reducing hepatic steatosis, decreasing ACE expression and increasing ACE2 expression. Enalapril 13-22 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 86-89 33049402-3 2021 AIM: The aim of the present study was to evaluate the Enalapril (ACE inhibitor) effects on the metabolic function and hepatic steatosis of obese mice evaluating Angiotensin Converting Enzymes (ACEs) expression. Enalapril 54-63 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 65-68 33469051-8 2021 We also showed that angiotensin-converting-enzyme inhibitor like enalapril, used to treat hypertension during CKD, induced a less severe hyperkalemia in N5/6 HKA2KO than in N5/6 WT mice. Enalapril 65-74 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 20-49 27844290-7 2017 Moreover, enalapril (an ACE inhibitor) enhanced the mechanical allodynia induced by a low dose of paclitaxel. Enalapril 10-19 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 24-27 30382174-7 2018 Moreover early treatment of UUO/CKD animals with an angiotensin-converting-enzyme inhibitor (ACE I), Enalapril, significantly attenuated cardiac fibrosis. Enalapril 101-110 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 52-81 33096237-6 2020 In a separate cohort of BALB/c mice, we repeated the study in the presence of the angiotensin converting enzyme inhibitor enalapril or a vehicle initiated 2 weeks post-TAC and administered for 6 weeks. Enalapril 122-131 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 82-111 32877912-4 2020 Moreover, we compare the gene expression pattern of liraglutide-treated mice to the gene expression pattern of mice treated with the angiotensin converting enzyme inhibitor, enalapril. Enalapril 174-183 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 133-162 30256910-0 2019 Chronic treatment with the ACE inhibitor enalapril attenuates the development of frailty and differentially modifies pro-and anti-inflammatory cytokines in aging male and female C57BL/6 mice. Enalapril 41-50 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 27-30 28758594-0 2017 Effects of Resveratrol and ACE Inhibitor Enalapril on Glucose and Lipid Profiles in Mice. Enalapril 41-50 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 27-30 25143333-4 2015 Following induction, groups were randomized to receive the ACE-inhibitor enalapril, the smooth muscle relaxant hydralazine (blood pressure control) or drinking water. Enalapril 73-82 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 59-62 28720491-3 2017 In this study, we investigated the treatment with an ACE inhibitor (Enalapril) and the Benznidazole (Bz) in a single and combination therapies (CT) in C57BL/6 mice infected with VL-10 strain of the T. cruzi. Enalapril 68-77 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 53-56 28696246-10 2017 Combined intervention with TUDCA and the angiotensin-converting enzyme inhibitor enalapril in 16-week-old db/db mice reduced albuminuria more efficiently than did either treatment alone. Enalapril 81-90 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 41-70 27076646-6 2016 Staining for p57, synaptopodin, podocin, and DAPI increased at FSGS day 28 and was augmented by the ACE inhibitor enalapril, which is consistent with a partial replenishment of podocytes. Enalapril 114-123 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 100-103 29124203-2 2015 Previously, we reported that ultraviolet B (UVB) irradiation enhanced angiotensin-converting enzyme (ACE) expression and angiotensin II levels in hairless mouse skin, and an ACE inhibitor, enalapril maleate (EM), accelerated repair of UVB-induced wrinkles. Enalapril 189-206 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 70-99 29124203-2 2015 Previously, we reported that ultraviolet B (UVB) irradiation enhanced angiotensin-converting enzyme (ACE) expression and angiotensin II levels in hairless mouse skin, and an ACE inhibitor, enalapril maleate (EM), accelerated repair of UVB-induced wrinkles. Enalapril 189-206 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 174-177 29124203-2 2015 Previously, we reported that ultraviolet B (UVB) irradiation enhanced angiotensin-converting enzyme (ACE) expression and angiotensin II levels in hairless mouse skin, and an ACE inhibitor, enalapril maleate (EM), accelerated repair of UVB-induced wrinkles. Enalapril 208-210 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 174-177